Compare Invesco DB Agriculture Fund (DBA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Neurocrine Biosciences Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.33B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 11× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DBA | NBIX | |
|---|---|---|
Market Cap | $1.33B | $14.60B |
Volume | 991,157 | 1,075,694 |
52-Week High | $29.49 | $185.50 |
52-Week Low | $25.44 | $123.10 |
Typical Hold Time | 24 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong YTD performance with 12.4% returns. The technical outlook remains bullish with moving averages signaling strength, though oscillators show neutral momentum. Recent news highlights agricultural ETF outperformance driven by weather risks and geopolitical tensions supporting commodity prices.
The fund's diversified agricultural futures exposure and 3.25% yield provide defensive characteristics amid market volatility. Key risks include high expense ratios (0.85%) and commodity price sensitivity. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish consolidation near all-time highs since 2020.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
